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Summary
Background: The p53, Rb, and Ras/PI3K pathways are impli-
cated in the development of the majority of human cancers.
A number of studies have established that these pathways
cooperate at the level of the cell cycle leading to loss of normal
proliferative controls. Here we have investigated how these
signals influence a second critical component of tumor forma-
tion—cell growth.
Results: We find that oncogenic Ras is sufficient to drive
growth via the canonical growth pathway, PI3K-AKT-TOR;
however, it does so relatively weakly and p53 loss does not
drive cell growth at all. Importantly, we identify a novel role
for the Rb family of tumor suppressors in directing cell growth
via a signaling pathway distinct fromPI3K-AKT-TOR and via an
E2F-independent mechanism. However, we find that strong,
sustained growth requires Rb loss together with Ras signaling,
identifying an additional mechanism by which these onco-
genic pathways cooperate and a critical role for Ras in
preserving the uptake of extracellular nutrients required for
biogenesis.
Conclusions:Wehave identified a new role for the Rb family in
cell biogenesis and show that, as for other processes associ-
atedwith tumor development, oncogenic cell growth is depen-
dent on cooperating oncogenes.
Introduction
The maintenance of tissue and body size is achieved by the
homeostatic regulation of cell growth (addition of volume/
mass), proliferation, and survival [1]. In contrast to unicellular
yeast—in which the rates of growth and proliferation are
mainly determined by nutrient levels—in animals, additional
levels of control are needed to differentially regulate the
distinct cell types found within multicellular organisms. So,
whereas the bloodstream (or equivalent) aims to supply
a relatively constant level of nutrients—cell growth, prolifera-
tion, and survival are regulated by additional extracellular
factors—growth factors, mitogens, and survival factors,
respectively. The formation of a tumor requires the loss of
each of these homeostatic controls, but as previous studies
have focused primarily on the role of proliferation and
apoptosis, the mechanisms underlying loss of growth controls
remain poorly understood.
The stringency of growth control has been clearly demon-
strated in vitro, in that mammalian cells will only add mass in
the presence of an extracellular growth factor—despite being2These authors contributed equally to this work
*Correspondence: alison.lloyd@ucl.ac.uksurrounded by nutrients—and that increasing levels of growth
factors result in increasing growth rates. In contrast, the
removal of growth factors triggers autophagy, resulting in
shrinkage and loss of cell mass [2–4]. These findings are
mirrored in studies in both mouse and Drosophila, which
have shown that the genetic manipulation of growth factor
pathways leads to changes in tissue and organism size [5, 6].
Thus, homeostasis reflects a level of growth factor signaling
sufficient to maintain the mass of a tissue, whereas to produce
more tissue—or a tumor— requires either increased growth
factor signaling or the deregulation of growth.
The evolutionarily conserved multiprotein kinase complex
mammalian target of rapamycin complex 1 (mTORC1) is a
central component of the growth regulatory network, control-
ling diverse processes such as protein and lipid synthesis,
mitochondrial metabolism, ribosome biogenesis, and auto-
phagy, which ultimately lead to cell growth. mTORC1 inte-
grates a number of signals that control cell growth, including
those from intracellular energy and amino-acid levels and
extracellular growth factors. In animals, the most well-charac-
terized growth factor is insulin-like growth factor-1 (IGF1),
which acts via phosphatidylinositol-3-kinase (PI3K) and AKT/
PKB to activatemTORC1, leading to phosphorylation of down-
stream effectors such as S6K and 4EBP—which play key roles
in translational control and to activation of SREBP1—an
important regulator of lipid biogenesis [7, 8].
There is accumulating evidence that specific oncogenic
signals deregulate cell growth, many of which—including
components of the PI3K-AKT pathway such as PTEN—
converge on mTOR signaling [9, 10], and inhibitors of mTOR
signaling such as rapamycin are showing clinical potential
[11]. Oncogenic Ras constitutively signals through the PI3K
pathway and has been shown to control cell growth in animal
models, although the downstream pathways are not clearly
defined [12]. p53 has been shown to influence metabolic path-
ways via a number of mechanisms, including the regulation of
autophagy and by the transcriptional control of nutrient trans-
porters and glycolytic enzymes [13]. Myc has also been shown
to regulate cell growth by controlling ribosome biogenesis
and protein synthesis, with increased myc levels resulting in
increased cell growth and size [14, 15]. Moreover, the deregu-
lation of both metabolic pathways and the biosynthetic
apparatus in cancer highlights the critical importance of
biosynthetic pathways in tumor formation [16, 17]. The coinci-
dent deregulation of RTK/Ras/PI3K, p53, and Rb signaling is
found in the majority of tumors [18]. Consistent with this, acti-
vated Ras together with loss of p53 and the Rb family coop-
erate to drive transformation in both in vitro and in vivo models
of tumor formation [19]. The cooperative effects of these onco-
genes on the cell cycle are well established but the way in
which these pathways interact to result in the loss of growth
control required for tumorigenesis remains unclear.
Primary Schwann cells have proven to be a powerful model
system for studying the regulation of mammalian cell growth,
which has previously been exploited to demonstrate the inde-
pendent regulation of growth and proliferative pathways and
how cell size is determined by the balance of extracellular
factors controlling these processes [2, 4]. The advantage of
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Figure 1. Ras Drives Weak Growth via PI3K-
AKT-TOR
(A) Coulter curves showing volume per cell of
populations of aphidicolin-cell-cycle-arrested
Schwann cells transduced with control vector
(SC-V), DNp53 (SC-DNp53), or DNp53 and Ras
(SC-DNp53Ras) following factor withdrawal
(0 hr) and after 24 hr in SATO medium with no
added factors (NF), IGF1 (IGF), or 3% FBS.
(B) Protein mass measurements of cells after
24 hr without factors or with IGF1 or 3% FBS
normalized to mass at time 0. Error bars repre-
sent means 6 SD of three independent experi-
ments.
(C) Western blot analysis of cell lysates collected
after 24 hr without factors or in the presence of
IGF1. See also Figure S1.
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1766using Schwann cells is that they are primary cells with intact
checkpoints that can be cultured indefinitely in defined condi-
tions, permitting the measurement of cell growth following
either the addition of an exogenous factor or a genetic change,
in the absence of any potentially collaborating exogenous
growth factors. In the present study, we have used this system
to determine how Ras, p53, and the Rb family affect cell
growth networks and found that Ras signaling and disruption
of the Rb family cooperate to drive robust cell growth in the
absence of signals normally provided by extracellular growth
factors. These findings identify a novel role for the Rb family
in tumorigenesis and provide further insight into how these
ubiquitous tumorigenic pathways interact to drive tumor
development.
Results
Loss of p53 Fails to Induce Cell Growth whereas
Oncogenic Ras Induces Weak Growth
Previous studies have shown that oncogenic Ras and loss
of the tumor suppressor p53 cooperate to stimulate prolifera-
tion, and more recent work has described how these two
signals synergize to induce a ‘‘cancer-related gene signature’’
[20–22]. To address whether inhibiting p53 is sufficient to
induce cell growth, we used a retroviral vector to express
a dominant-negative form of p53 (DNp53), which is able to alle-
viate a cell-cycle arrest induced by g-irradiation or oncogenic
Ras in primary Schwann cells [23] (see Figures S1A and S1B
available online) and determined cell growth using two criteria
as follows: (1) changes in cell volume, measured in cell-cycle
arrested cells and (2) by the addition of protein mass. As in
previous studies [3, 4], control Schwann cells infected with
the vector construct (SC-V) lost volume and mass once exog-
enous growth factors were removed, consistent with the onset
of autophagy (Figures 1A and 1B; Figure S1C). Somewhat
surprisingly, we found that DNp53-expressing cells behaved
as control cells, losing volume and mass, at a similar rate,
following the removal of extracellular growth factors (Figures
1A and 1B) indicating that loss of p53 is not sufficient to drive
cell growth. We next coexpressed constitutively active Ras inboth Schwann cells (SC-Ras) and the
DNp53-expressing Schwann cells (to
avoid the cell-cycle inhibition induced
in primary cells by oncogenic Ras [21])
and found that in both cases, oncogenic
Ras was able to drive cell growth atsimilar rates (Figures 1A and 1B; Figures S1C and S1D).
However, the growth was relatively weak—when compared
to growth induced by fetal bovine serum (FBS), an ill-defined
yet potent stimulator of cell growth (Figures 1A and 1B) [2,
4]. The rate of Ras-induced growth was similar to the rate
achieved by saturating concentrations of the growth factor
IGF1 [2, 4] and IGF1-stimulation failed to potentiate Ras-
induced growth indicating that both signals may be acting
through the same pathway (Figure 1A). Consistent with this,
activation of the PI3K-AKT-TOR pathway was comparable in
IGF1-treated control or Ras-expressing cells (Figure 1C)
and—as has previously been shown for IGF1 [24]—Ras-driven
growth was blocked by the addition of the PI3K inhibitor,
LY294002 (Figure S1E).
Loss of the Rb Family Drives Cell Growth
To determine the role of the Rb family in growth control, we
initially used SV40 LT antigen (LT) as a tool to remove the entire
Rb family and which by sequestering p53 also inactivates the
p53 pathway [25]. Interestingly, we found that LT expression
was sufficient to drive robust increases in both cell volume
and cell mass and at rates consistently higher than stimulated
by saturating levels of IGF1 in normal Schwann cells (Figures
2A and 2B; Figures S2A and S2B). We determined mass accu-
mulation in both non-cell-cycle arrested cells and in arrested
cells (using two separate methodologies) and obtained similar
rates of protein accumulation (Figure 2B; Figures S2A and
S2B). Importantly, we were unable to detect induction of the
PI3K-AKT-TOR pathway, suggesting that LT does not act by
promoting the autocrine production of a factor such as IGF1
and instead is driving cell growth via a distinct pathway (Fig-
ure 2C). Moreover, in contrast to Ras-expressing cells, the
growth observed in LT cells was potentiated by IGF1. This
synergy was not associated with a further increase in signaling
through the PI3K-AKT-TOR pathway, indicating that the two
signals act through parallel pathways (Figure 2C). Treatment
with the MEK inhibitors U0126 or PD184352, previously
demonstrated to have no effect on IGF1-induced growth
[24], also had no effect on LT-induced growth indicating that
signaling through the ERK pathway was not required despite
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Figure 2. SV40 LT Expression Drives Cell Growth
in the Absence of PI3K-AKT-TOR Activation
(A) Coulter curves showing volume per cell of
a population of aphidicolin-arrested Schwann
cells infected with SV40 LT antigen (SC-LT).
Volume measurements were made upon factor
withdrawal (0 hr) and after 24 hr without factors
(NF) or with IGF1 (IGF).
(B) Protein mass measurements of control (SC-V)
and SC-LT cells after 24 and 48 hr without factors
or treated with IGF1 were normalized to mass at
the time of factor withdrawal. Error bars repre-
sent means 6 SD of three independent experi-
ments.
(C) Western blot analysis of cell lysates collected
following factor removal (0 hr) and after 24 hr
without factors (NF) or with IGF1 (IGF).
(D) Aphidicolin-arrested SC-LT cells were treated
with 15 mM U0126 (U0), 0.1 mM rapamycin
(Rapa), 15 mM LY294002 (LY), or vehicle (NF)
and volume per cell was measured after 24 hr
without factors.
(E) Coulter curves showing volume per cell of
a population of aphidicolin-arrested fibroblasts
infected with LT (Fb-LT) or control vector (Fb-V)
upon factor withdrawal (0 hr) and after 24 hr
without factors (NF) or with IGF1.
(F) Protein mass measurements of control (Fb-V)
and LT (Fb-LT) infected fibroblasts after 24 and
48 hr without factors or treated with IGF1. Values
were normalized to mass at the time of factor
withdrawal. Error bars represent means 6 SD
of three independent experiments. See also
Figure S2.
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1767being required for Schwann cell proliferation (Figure 2D;
Figures S2C–S2E). In LT cells treated with rapamycin or
LY294002, however, growth was abolished suggesting that
although PI3K signaling is not activated, basal flux through
mTORC1 is still required for cell growth (Figure 2D). A basal
level of signaling PI3K affecting cell growth was further sug-
gested by the observation that control cells treated with
LY294002 lose additional volume even in the absence of
factors (Figure S2F).
To confirm that the ability of LT to drive cell growth was
not specific to Schwann cells, we repeated the experiments
in another cell-type—primary rat fibroblasts. We infected
the fibroblasts with LT (Fb-LT) or control vector (Fb-V) and
measured the ability of the cells to add volume and protein
mass in the absence of extracellular growth factors. As for
the Schwann cells, we found that LT was able to drive robust
growth in the absence of extracellular factors whereas the
control cells failed to grow (Figures 2E and 2F; Figure S2G).
Moreover, as for the Schwann cells this was not associated
with elevated signaling through the PI3K-AKT pathway
(Figure S2H).
To determine the role of the Rb family in LT-driven growth,
we made use of two well-characterized mutants that differen-
tially affect Rb family interactions (reviewed in [25]). Western
blot analysis confirmed that the LT point mutants—one unable
to bind the entire Rb family (LT-K1), the second a mutant
that differentially inactivates Rb compared to p107/p130
family members (LT-5110)—were expressed at similar levels
to wild-type (WT) (LT) (Figure 3A). Cells expressing LT-K1
behaved similarly to control cells, losing volume over time—demonstrating that Rb family inactivation was critical for the
growth-promoting function of LT. These results also confirmed
the inability of p53 loss to induce cell growth as p53 binding
and inhibition is retained by the LT-K1 mutant. In contrast,
cells expressing the LT-5110 mutant did grow (Figures 3A
and 3B), suggesting that it is loss of Rb function that is mainly
responsible for driving cell growth.
We then used the E7 protein from HPV16 (which targets the
Rb family of proteins for destruction but leaves p53 intact) to
confirm that loss of the Rb family was sufficient to drive cell
growth. In both control cells and cells expressing an Rb
family-binding defective form of E7, the removal of growth
factors led to a decrease in protein mass. In contrast, WT E7
was able to drive the addition of cell mass (Figure S3A), indi-
cating that loss of the Rb family was sufficient to stimulate
cell growth. Moreover, growth occurred in the absence of
detectable signaling via the PI3-K pathway (Figure S3B).
To directly assess the specific role of Rb, we transfected
primary Schwann cells with small interfering RNAs (siRNAs)
targeted to Rb, which led to a greater than 70% reduction in
Rb protein when compared to cells transfected with the
nonspecific control (Figure 3C) and found that Rb knockdown
was sufficient to induce an accumulation of protein mass (Fig-
ure 3C; Figure S3C). The growth was less than that stimulated
by LT, which may reflect incomplete knockdown; however, it
may also indicate a role for other members of the Rb family.
Depleting Rb in DNp53-expressing cells had no additional
effect on growth (Figures S3D and S3E). Taken together, these
data demonstrate that loss of Rb is sufficient to drive cell
growth, that loss of p53 is neither sufficient nor required for
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Figure 3. Loss of Rb Is Sufficient to Drive Cell
Growth
(A) Representative Coulter curves showing the
volume per cell of cell-cycle arrested populations
expressing either LT or LT point mutants (LT-K1
and LT-5110) at the time of factor withdrawal
(0 hr) and after 24 hr without factors (NF). Western
blot analysis of LT is shown.
(B) Protein mass measurements of cells after
24 hr without factors (NF) or supplemented with
3% FBS, normalized to mass at time of factor
withdrawal. Error bars represent two indepen-
dent experiments 6 SD.
(C) Rb knockdown. Western blot analysis of total
Rb levels in cells transfected with a nonspecific
siRNA duplex (Con) or with an oligo specific for
Rb. Immunostaining of Rb protein in siRNA trans-
fected cells. Protein mass measurements of
control cells and cells with siRNA against Rb after
48 hrwithout factors or treatedwith IGF1, normal-
ized to mass at time of factor withdrawal. Error
bars show mean of triplicates 6 SD. One way
ANOVA with Tukey’s post hoc test was per-
formed. See also Figure S3.
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1768growth, and that p53 loss does not act synergistically with Rb
loss to drive cell growth.
Growth Is Uncoupled from Effects on Cell-Cycle
and E2F-Dependent Transcription
The size of proliferating cells is determined by the relative rates
of growth and proliferation. Comparison of the effects of LT on
growth and proliferation showed that whereas SC-LT cells
proliferated at a similar rate in the presence or absence of
FBS, the growth rate was significantly lower in cells cultured
in the absence of factors resulting in the production of smaller
cells (Figure S4A). This is because serum is a more potent
growth factor than LT (Figures 1A and 2A), which also means
that the more slowly dividing SC-DNp53 cells are larger than
the SC-LT cells at time 0 hr of the size experiments, as they
have been cultured in serum (Figure 1A). These differential
effects also suggested that LT might regulate the cell-cycle
and cell growth by distinct mechanisms. Consistent with this,
whereas SC-LT cells were able to proliferate and grow in the
absence of factors, the LT-5110 mutant, while able to drive
cell growth, was unable to induce the expression of cyclin A
or trigger entry into the cell-cycle, showing that Rb regulation
of cell growth can be uncoupled from effects on the cell cycle
(Figures 4A and 4B; Figures 4B and S4C). As cyclin A is a key
E2F cell-cycle target, these results suggested that inhibition
of Rb causes cell growth via an E2F-independent mechanism.
To confirm this, we tested the ability of constitutive E2F activity
to drive cell growth and the ability of siRNAs to E2F1 to block
LT-induced growth. Because E2F overexpression is reported
to induce apoptosis in part via p53-dependent mechanisms,
we used cells expressing DNp53 to express E2F1. We intro-
duced hemagglutinin (HA)-tagged E2F1 into these cells and
found that whereas E2F1 overexpression was sufficient to effi-
ciently induce cyclin A expression (Figure S4D), it was unable
to drive cell growth (Figure 4C). Moreover, we found that
despite an efficient knockdown of E2F1, LT-induced growth
was unaffected (Figure S4E). These results are consistent
with Rb-loss driving growth by an E2F-independent mecha-
nism and independent from effects on the cell cycle.
To determine whether the growth induced by Rb was the
result of an increase in biosynthetic pathways, we analyzedthe rates of de novo protein and lipid biosynthesis following
short-term labeling with radiolabeledmethionine and pyruvate
and measured their incorporation into protein and lipid frac-
tions, respectively. We found that the SC-LT cells had signifi-
cantly higher rates of both protein and lipid biosynthesis
compared to control cells (Figures 4D and 4E). We then per-
formed pulse-chase experiments to determine the protein
degradation rates in the two cell types and found that the
half-lives of the proteins were similar in the two cell types,
arguing that an increase in biosynthesis rather than an inhibi-
tion of degradation pathways was responsible for the growth
of the LT-expressing cells (Figures 4F and 4G). We also
compared autophagic rates in the two cell types in the
absence of factors by both immunofluorescence and western
blot analysis of LC3. We found that both SC-V and SC-LT cells
showed a dramatic upregulation of LC3-positive autophagic
structures following growth factor removal (Figure S4F)
indicating the onset of autophagy. To quantify the flux, we
compared the levels of LC3-I and LC3-II following growth
factor removal and found, in the absence of chloroquine, a
similar decrease in LC3-I levels and an increase in LC3-II levels
in the SC-V and SC-LT cells. However, upon chloroquine treat-
ment we detected higher levels of LC3-II in the SC-LT cells,
arguing that autophagic flux is higher in the LT-expressing
cells (Figure S4G). These results clearly demonstrate that
a decrease in autophagic rates is not responsible for the
increase in cell growth induced by LT expression and that
biogenic processes drive the cell growth seen in the LT-ex-
pressing cells.
LT Cooperates with Oncogenic Ras to Drive Strong,
Sustained Growth
Our findings demonstrate that oncogenic Ras drives weak
growth through canonical activation of the PI3K pathway (Fig-
ure 1), whereas loss of Rb acts via a distinct pathway (Figure 2).
To test the cooperation between these signals, we expressed
oncogenic Ras in SC-LT cells. Similarly to the effects of IGF1,
we found that the Ras signal synergized with loss of the
Rb family to drive stronger growth (Figures 5A and 5B) and
without a further increase in signaling through the PI3K
pathway compared to SC-DNp53Ras cells, which grow poorly,
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Figure 4. Rb-Induced Growth Is Uncoupled from
Effects on Cell Cycle and E2F-Dependent Tran-
scription and Involves an Increase in Biosynthetic
Pathways
(A) Counts of bromodeoxyuridine-positive cells
after 24 hr without factors (NF) or with 3% FBS.
Error bars show mean of triplicates 6 SD.
(B) Western blot analysis of cyclin A, 24 hr after
withdrawal of factors or 24 hr following the addi-
tion of IGF1 or FBS as indicated.
(C) Coulter curves showing volume per cell
of arrested SC-DNp53 cells transfected with
hE2F1-HA (E2F1) or control vector (Vector) after
24 hr without factors (NF). Cells supplemented
with IGF1 were included as positive control.
(D) Incorporation of [2-14C] pyruvate into the lipid
fraction of SC-V and SC-LT cells following a 4 hr
labeling period 24 hr following the removal of
factors. Values shown are the mean of three inde-
pendent experiments 6 SEM.
(E) Incorporation of [35S]-methionine into the
protein fraction of SC-V and SC-LT cells following
a 45 min labeling period, 24 hr following the
removal of factors in the absence or presence
of cycloheximide (CXM). Values shown are the
mean of three independent experiments 6 SEM.
Student’s t test was performed.
(F) Levels of [35S]-methionine in the protein frac-
tion of SC-V and SC-LT cells over time, following
a 2 hr pulse, 24 hr following the removal of
factors. Numbers are expressed as fold change
relative to SC-V cells at 0 hr and show the
increased amount of incorporation by the SC-LT
cells.
(G) Shown are the data from (F), when the amount
at time 0 hr for each cell-type is corrected to 1 and
thus shows the relative half-lives of the labeled
proteins. Values shown are the mean of three
independent experiments 6 SEM. One-way
ANOVA with Tukey’s post hoc test was per-
formed. See also Figure S4.
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1769indicating that the synergy does not act at the level of PI3K
signaling (Figure 5C; Figure S5A). Interestingly, we found that
Ras and LT also cooperated in a secondmanner—to drive sus-
tained growth. We found that although SC-LT cells cultured
without factors added protein mass progressively for 48 hr,
after this point the growth stalled. However, cells coexpress-
ing Ras continued to add mass and stalled SC-LT cells could
be reinduced to grow by treatment with IGF1 (Figures 6A and
6B). We noted that stalled SC-LT cells developed a ‘‘starved’’
appearance, similar to that seen in normal cells following
removal of glutamine from the medium. As PI3K-AKT-TOR
signaling has been shown to regulate nutrient transporter
expression and localization at the cell-surface [26, 27], we
speculated that the PI3K signal induced by Ras and IGF1
and absent in the LT-expressing cells was required for the
maintenance of nutrient uptake that would be predicted to
be necessary for sustained cell growth. To determine whether
this was the case, we measured the uptake of two radioac-
tively labeled nutrients known to be important for growth—
glutamine and glucose (using 2DG; a nonmetabolizable
glucose analog) in cells over time, following the removal of
factors. In SC-LT cells, we found that whereas nutrient uptake
rates weremaintained at 24 hr following the removal of factors,
by 48 hr the levels had decreased substantially (Figures 6C
and 6D), coincident with when the cells stopped growing. In
contrast, nutrient uptake was maintained in the Ras-express-
ing cells, which continued to grow (Figures 6C and 6D). Todetermine the functional significance of a decrease in nutrient
uptake on growth, we initially tested the effects of glutamine
removal on LT and LT-Ras cells and found that both required
extracellular glutamine to grow (Figure S6A). mTORC1 is regu-
lated by amino acid levels and the complex has recently been
reported to relocalize and, as a result, lose activity upon amino
acid starvation providing an indicator of intracellular nutrient
levels, although the pattern varied between the cell types
tested [28, 29]. We therefore used alterations in the subcellular
localization of mTOR as a read-out of a significant decrease in
nutrient levels within the cell. In Schwann cells, we found that
amino acid starvation caused mTOR to redistribute from the
periphery to discrete puncta in the perinuclear region (Fig-
ure 6E). We then examined the localization of mTOR in SC-
LT cells and control vector cells following the removal of
factors and found that whereas at early time-points mTOR
staining was diffuse throughout the cell, at a later time-point,
when nutrient uptake levels had declined, we found a dramatic
change in the localization of mTOR to form large clusters
near the perinuclear region, although mTOR levels remained
constant (Figure 6E; Figures S6B–S6D). Much of the mTOR
colocalized with lysosomes, which also moved to the perinu-
clear region following long-term growth factor removal (Fig-
ure S6D). This result is consistent with loss of mTOR activity
in response to lowered amino-acid levels within the cell [28],
providing a mechanistic explanation for the inhibition of cell
growth in these cells.
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Figure 5. LT and Oncogenic Ras Cooperate to Drive Strong Growth
(A) Representative volume curves of arrested cell populations at point of factor withdrawal (0 hr) and after 24 hr without factors (NF). Cells coexpress either
DNp53 and RasVal12 (SC-DNp53Ras), LT and vector (LT), or LT and RasVal12 (LT-Ras). Mean growth rates (change in mean volume per hr) are given for four
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(B) Change in total protein mass in these cells after 48 hr without factors compared to time 0 hr for each cell type. Data are presented as mean6 SEM of five
independent experiments.
(C) AKT and mTORC1 activation levels after 24 hr without factors as shown by western blot analysis of AKT (Ser 473) and p70S6 kinase phosphorylation.
Total AKT is used to assess protein loading. See also Figure S5.
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The formation of a tumor requires the loss of normal growth
controls; therefore, the genetic changes responsible for tumor
formation must be capable of driving cell growth. Yet, despite
the identification of the key genetic drivers for many tumor
types, it remains poorly understood how and which of these
genetic changes act to induce the increases in mass required
for tumor formation. In the present study, we have character-
ized the ability of three major oncogenic pathways implicated
in the majority of human cancers to induce cell growth and
found that two of these, oncogenic Ras and Rb family loss,
are each sufficient to drive growth. We found that Ras is
a relatively weak driver of growth, whereas loss of Rb induces
stronger growth but is unable to produce sustained growth.
Instead, as for other aspects of tumor formation (such as
proliferation), we find that these two pathways cooperate to
produce the strong, sustained growth likely to be required to
form a rapidly growing tumor. This novel mechanism of onco-
genic cooperation provides further insight into how oncogenic
changes may act together to promote cancer and potentially
offers further novel strategies for therapeutic targeting.
Loss of the Rb family has been linked to various aspects of
tumorigenesis with important roles in cell-cycle control, cell
senescence, and changes in differentiation state [30]. Here,
we have identified a further consequence of Rb-family loss,
in that it is sufficient to directly drive cell growth and acts
together with oncogenic Ras signaling to drive robust growth.
Interestingly, we find that the effects of Rb loss on the cellcycle and cell growth pathways can be separated, providing
another example of the separation of these important and
often coordinated cellular processes. Thus, whereas effects
on the cell cycle are mediated by E2F-dependent activation
of cyclin/cdk expression, the effects on cell growth are inde-
pendent of E2F activity. This separation is demonstrated
most clearly with the mutant of LT (LT-5110) that is able to
drive cell growth but not proliferation. Somewhat counterintu-
itively, we and others find that cells in which the Rb family is
inactivated are usually smaller than normal cells [31, 32],
however this is readily explained by our findings that LT has
a more dramatic effect on the cell cycle than on cell growth,
which will lead to cells proliferating at a smaller cell size and/or
the potency of serum as a growth factor—conditions in which
most cells are cultured in vitro. These differential effects on the
cell cycle and cell growth can explain why tumor cells are
sometimes smaller than their normal counterparts despite
having aberrant growth pathways and emphasize the separate
regulation of the growth and proliferative pathways.
We find that LT drives growth without promoting AKT/TOR
activity. Very few other growth-promoting pathways have
been described, though a direct role for the transcription
factor and proto-oncogene c-myc in regulating growth is well
established [33]. We were unable to detect increased levels
of c-myc in LT-expressing cells, suggesting that Rb loss
does not drive growth by this mechanism—although, consis-
tent with other reports [34], myc was induced by constitutively
active Ras (Figure S5B). In Drosophila, overexpression of the
cyclin D/cdk4 complex, an upstream regulator of Rb, was
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Figure 6. Ras Signaling Maintains Nutrient Uptake
and Allows Sustained Growth
(A) Cells coexpressing LT and control vector or LT
and RasVal12 cultured in the absence of factors for
96 hr. Protein mass measurements were made at
24 hr intervals and normalized to mass at time of
factor withdrawal. Error bars show mean of tripli-
cates 6 SD.
(B) Total protein mass of SC-LT cells over time. Cells
were cultured without factors for 48 hr and subse-
quently maintained in the absence of factors or stim-
ulated with IGF1 andmeasured 24 hr later. Error bars
show mean of triplicates 6 SD.
(C) Uptake of tritiated glutamine ([3H]Gln) in cells
without factors over time, normalized to uptake at
time of factor withdrawal. Error bars show means
of three independent experiments 6 SEM.
(D) Uptake of tritiated 2-deoxyglucose ([3H]2DG) in
cells without factors over time, normalized to uptake
at time of factor withdrawal. Data are presented as
mean 6 SEM of four independent experiments.
(E) mTOR localization: Schwann cells in complete
culture medium were transferred to medium without
amino acids for 40 min, followed by stimulation with
amino acids for a further 20 min. SC-LT cells were
cultured without factors. Cells were fixed and immu-
nostained for mTOR. The percentage of each cell
containing mTOR-positive pixels was quantified
and normalized either to SC cells in full medium or,
in the case of LT, to cells after 1 hr without factors.
Scale bar represents 15 mm. See also Figure S6.
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1771reported to cause cell enlargement [35]; however, this was via
an Rb-independent mechanism, which involved the regulation
of mitochondrial activity [36]. It has been established that Rb
can repress transcription of components of the translational
machinery through interactions with subunits of the RNA
pol I and III transcription factor complexes [37, 38]. Because
protein synthesis is an essential element of cell growth, it is
to be expected that disrupted regulation of the synthetic
machinery will contribute to the ability of Rb loss to drive cell
growth. However, there is no evidence to suggest that dysre-
gulation of RNA pol I and III transcription is sufficient to drive
growth, and it is likely that Rb acts atmany levels to coordinate
cell growth. This is supported by our microarray gene expres-
sion analysis (unpublished data), which indicates that loss of
Rb also induces E2F-independent global changes in RNA pol
II transcription.
Consistent with other studies, we found that oncogenic Ras
signaling and activation of the PI3K growth cascade was suffi-
cient to induce cell growth but somewhat to our initial surprise,
despite robust activation of the canonical growth pathway, cell
growth in the absence of synergizing factors was weak.However, these findings are consistent
with other studies in which constitutive
activation of the AKT-TOR pathway was
also found to drive relatively weak growth
[24, 39]. Interestingly, despite previous
reports that p53 can act as a metabolic
regulator and is able to induce autophagy
[13], we found that loss of p53 had no
direct effect on cell growth. Although we
showed that the Ras-AKT-TOR pathway
is relatively weak in driving cell growth,
we also showed that the pathway cooper-
ated with the loss of Rb, to drive strongsustained growth. Interestingly, a recent genetic study in
Drosophila has also found synergy between the mTOR
pathway and Rb [40]. Using an in vivo synthetic lethality screen
to identify genes that synergistically induced cell death in Rb-
negative cells, they identified TSC2—an upstream inhibitor of
mTORC1 that is targeted by Ras/PI3K signaling. Significantly,
the authors attributed the lethality to a combination of oxida-
tive and endoplasmic reticulum stress signals, which they
speculated to be mediated in part by elevated levels of protein
synthesis—an in vivo corroboration of our finding that Rb
loss and Ras together induce strong growth and perhaps an
indication of how these findings may be exploited for thera-
peutic purposes.
Nutrients are supplied systemically in animals; therefore
regulating their uptake can provide a means of cell growth
control and has been proposed as a tumor suppressor mech-
anism [26]. In agreement with other studies, we found that
PI3K-AKT-TOR signaling is required to maintain nutrient
uptake [27, 41]. We established that Rb loss is capable of
driving cell growth but found that this growth pathway is not
sustainable—loss of Rb does not activate the PI3K cascade,
Current Biology Vol 22 No 19
1772and consequently cells lose access to nutrients and eventually
stall in their growth. Thus, we have identified regulation of
nutrient transport as a novel mechanism by which Rb loss
and oncogenic Ras synergize. Our findings underscore the
importance of the PI3K pathway in cell growth but demon-
strate the necessity for the coactivation of other oncogenic
pathways in order to achieve the robust growth associated
with aggressive tumor formation.
Experimental Procedures
Cells
Schwann cells and fibroblasts were isolated from P7 rat sciatic nerve and
cultured as described previously [23]. Normal culture medium for Schwann
cells is Dulbecco’smodified Eagle’smedium (DMEM) (low glucose) contain-
ing 3% FBS, 1 mM forskolin, and 20 ng/ml neuregulin. Fibroblasts were
routinely cultured in DMEM containing 10% FBS. For factor withdrawal
experiments, Schwann cells were seeded onto dishes coated with poly-L-
lysine (PLL), fibronectin and laminin in normal culture medium whereas
fibroblasts were seeded onto dishes coated with PLL only. Factors
were removed by performing three washes in modified SATO-defined
medium (DMEM supplemented with 100 mg/ml BSA, 60 ng/ml progesterone,
16 ug/ml putrescine, 40 ng/ml selenium, 50 ng/ml triiodothyrine, 50 ng/ml
thyroxine) and then replacing with SATO containing transferrin (100 mg/ml)
with or without IGF1 (100 ng/ml).
Size Measurements
We seeded 105 cells onto triplicate wells of six-well PLL-laminin-fibronectin
coated dishes in normal culture medium (PLL only for the fibroblasts) and
were arrested using 1 mg/ml aphidicolin for 24 hr. Factors were removed
by washing as described, and the cells were placed into SATO-defined
medium containing transferrin (100 mg/ml) with or without IGF1 (100 ng/ml)
and 0.8 mg/ml aphidicolin. Any inhibitors were added at this time point and
15 min prior to the addition of IGF1. The time 0 hr point was then collected
by trypsinisation, resuspended in isotonic solution, and measured using
a Beckman Multisizer 4 Coulter Counter (10,000 cells per reading). Changes
in cell size were then detected 24 hr later.
Statistical Analyses
Unless otherwise indicated in the figure legend, one-way ANOVA with
Newman-Keuls post hoc analysis was performed for all tests of significance.
In all cases: *p < 0.05, **p < 0.01, ***p < 0.001, ns = not significant.
Supplemental Information
Supplemental Information includes six figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.cub.2012.07.040.
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